

Mitesh J Borad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8473936/publications.pdf>

Version: 2024-02-01

158
papers

12,798
citations

61687

45
h-index

30277

107
g-index

193
all docs

193
docs citations

193
times ranked

15771
citing authors

#	ARTICLE	IF	CITATIONS
1	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	6.1	34
2	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e508-e528.	2.4	36
3	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
4	Synergistic combination of cytotoxic chemotherapy and cyclinâ€¢dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6
5	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 81-90.	1.2	3
6	Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. <i>Cancer Prevention Research</i> , 2022, 15, 121-128.	0.7	9
7	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
8	Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 125-131.	1.9	12
9	Isocitrate Dehydrogenaseâ€¢Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. <i>JCO Precision Oncology</i> , 2022, 6, e2100156.	1.5	10
10	Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 463-463.	0.8	1
11	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 190-190.	0.8	2
12	Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 288-297.	0.6	6
13	Reply to A. Rizzo et al. <i>JCO Precision Oncology</i> , 2022, 6, e2200061.	1.5	0
14	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
15	Tilsetolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1-13.	1.9	8
16	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. <i>Cancers</i> , 2022, 14, 2056.	1.7	24
17	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. <i>JCO Precision Oncology</i> , 2022, , .	1.5	4
18	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11

#	ARTICLE	IF	CITATIONS
19	Final results from ClariDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (<i>IDH1</i>) mutation.. Journal of Clinical Oncology, 2021, 39, 266-266.	0.8	41
20	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 2021, 39, 1072-1080.	1.2	4
21	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 2021, 12, 1930.	5.8	7
22	Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers, 2021, 13, 1186.	1.7	3
23	Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist, 2021, 26, 569-578.	1.9	23
24	Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precision Oncology, 2021, 5, 733-743.	1.5	11
25	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. JCO Precision Oncology, 2021, 5, 432-441.	1.5	16
26	Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multi-center prospective study. Molecular Genetics and Metabolism, 2021, 132, S34-S35.	0.5	1
27	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	1.8	10
28	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 2021, 13, 2968.	1.7	63
29	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	1.5	2
30	P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology, 2021, 32, S333.	0.6	2
31	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. Journal of Hepatology, 2021, 75, 351-362.	1.8	35
32	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	5.1	178
33	Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 641044.	1.3	2
34	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
35	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biology, 2021, 22, 227.	3.8	13
36	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. JAMA Oncology, 2021, 7, 1669.	3.4	194

#	ARTICLE	IF	CITATIONS
37	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205
38	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 11-11.	0.4	8
39	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	2.3	477
40	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	1.3	17
41	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, . .	0.5	11
42	Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103535.	2.0	10
43	ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. <i>Science Advances</i> , 2021, 7, eabl8213.	4.7	112
44	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	1.3	8
45	Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy. <i>Mayo Clinic Proceedings</i> , 2020, 95, 306-318.	1.4	5
46	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
47	Second-line therapies in advanced biliary tract cancers. <i>Lancet Oncology</i> , The, 2020, 21, e29-e41.	5.1	77
48	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. <i>Oncologist</i> , 2020, 25, 380-e763.	1.9	10
49	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17
50	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	3.4	124
51	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
52	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	0.5	12
53	Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. <i>Cancer Research</i> , 2020, 80, 4324-4334.	0.4	36
54	Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells. <i>Journal of Hepatology</i> , 2020, 73, S122.	1.8	4

#	ARTICLE	IF	CITATIONS
55	Updated data from an ongoing study with ADP-A2AFP spear T-cells. Journal of Hepatology, 2020, 73, S910-S911.	1.8	1
56	Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatology Communications, 2020, 4, 1781-1792.	2.0	9
57	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	5.1	620
58	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precision Oncology, 2020, 4, 557-569.	1.5	35
59	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 671-684.	5.1	923
60	Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. Hpb, 2020, 22, 1490-1495.	0.1	15
61	Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. European Journal of Surgical Oncology, 2020, 46, 789-795.	0.5	15
62	Advances in the treatment of biliary tract cancers. Current Opinion in Gastroenterology, 2020, 36, 1.	1.0	10
63	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1630-1637.	2.9	472
64	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 1063-1078.	1.1	14
65	Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. Molecular Therapy - Oncolytics, 2020, 18, 546-555.	2.0	9
66	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nature Medicine, 2020, 26, 878-885.	15.2	297
67	FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with <i>FGFR2</i> fusions or rearrangements.. Journal of Clinical Oncology, 2020, 38, TPS592-TPS592.	0.8	14
68	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (<i>FGFR2</i>) gene rearrangements (FOENIX-CCA3).. Journal of Clinical Oncology, 2020, 38, TPS600-TPS600.	0.8	34
69	Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. Hepatobiliary Surgery and Nutrition, 2020, 9, 501-504.	0.7	0
70	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	1.7	0
71	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	1.7	1
72	HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. Hepatology, 2019, 69, 131-142.	3.6	27

#	ARTICLE	IF	CITATIONS
73	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 745-750.	0.6	17
74	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 554-561.	0.6	31
75	Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular clinical analysis and potential targeted approach. <i>Hepatology International</i> , 2019, 13, 490-500.	1.9	36
76	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	3.4	335
77	Hepatocytes direct the formation of a pro-metastatic niche in the liver. <i>Nature</i> , 2019, 567, 249-252.	13.7	263
78	MetaMarker: a pipeline for <i>de novo</i> discovery of novel metagenomic biomarkers. <i>Bioinformatics</i> , 2019, 35, 3812-3814.	1.8	10
79	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1432-1438.	0.5	63
80	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	0.7	34
81	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 684-692.	1.2	30
82	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 379-386.	0.1	11
83	Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. <i>Translational Oncology</i> , 2019, 12, 143-153.	1.7	37
84	E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. <i>Investigational New Drugs</i> , 2019, 37, 636-645.	1.2	22
85	Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS462-TPS462.	0.8	5
86	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	1.1	22
87	Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). <i>International Journal of Surgery</i> , 2018, 52, 171-179.	1.1	38
88	Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 153-161.	2.9	51
89	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2018, 67, 2338-2351.	3.6	92
90	Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86

#	ARTICLE	IF	CITATIONS
91	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
92	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1054-1062.	0.6	110
93	Emerging role of precision medicine in biliary tract cancers. <i>Npj Precision Oncology</i> , 2018, 2, 21.	2.3	27
94	Novel immunotherapy strategies for hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	1.0	6
95	Chromoanasythesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. <i>BMC Cancer</i> , 2018, 18, 738.	1.1	13
96	Oncolytic Adenoviruses in Gastrointestinal Cancers. <i>Biomedicines</i> , 2018, 6, 33.	1.4	8
97	Prevalent hepatitis B surface antigen among first-time blood donors in Gabon. <i>PLoS ONE</i> , 2018, 13, e0194285.	1.1	16
98	Exploring the role of oncolytic viruses in hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 971-986.	1.0	9
99	Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. <i>British Journal of Cancer</i> , 2018, 118, 1580-1585.	2.9	16
100	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e727-e734.	0.9	3
101	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). <i>Targeted Oncology</i> , 2017, 12, 201-209.	1.7	25
102	Immunotherapy in pancreatic cancer treatment: a new frontier. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 168-194.	1.4	73
103	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
104	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	1.2	647
105	Quantitative Imaging System for Cancer Diagnosis and Treatment Planning: An Interdisciplinary Approach. , 2017, , 152-175.		3
106	Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	2.0	29
107	Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1583-1591.	1.4	23
108	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 127-132.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review. <i>Case Reports in Gastroenterology</i> , 2017, 10, 605-612.	0.3	15
110	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	0.8	55
111	Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. <i>Diagnostics</i> , 2017, 7, 50.	1.3	10
112	Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations. <i>Journal of Clinical Medicine</i> , 2017, 6, 26.	1.0	23
113	Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 39-49.	6.0	32
114	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 11-18.	6.0	32
115	Oncolytic virotherapy in upper gastrointestinal tract cancers. <i>Oncolytic Virotherapy</i> , 2017, Volume 7, 13-24.	6.0	11
116	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	0.8	133
117	Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. <i>Cureus</i> , 2017, 9, e1517.	0.2	2
118	The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 789-796.	0.6	26
119	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016, 34, 96-103.	1.2	2
120	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. <i>Cancer Letters</i> , 2016, 380, 163-173.	3.2	72
121	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. <i>Scientific Reports</i> , 2016, 6, 25.	1.6	32
122	Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. <i>Cancer Investigation</i> , 2016, 34, 57-63.	0.6	0
123	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 439-447.	1.9	85
124	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 264-268.	1.0	44
125	Oncolytic viruses: perspectives on clinical development. <i>Current Opinion in Virology</i> , 2015, 13, 55-60.	2.6	19
126	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	3.2	39

#	ARTICLE	IF	CITATIONS
127	IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. <i>Hepatology</i> , 2015, 61, 1627-1642.	3.6	115
128	A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. <i>Cancer Investigation</i> , 2015, 33, 172-179.	0.6	4
129	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1475-1481.	0.8	152
130	Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements. <i>PLoS ONE</i> , 2014, 9, e87113.	1.1	14
131	Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2014, 34, 456-464.	1.8	106
132	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	1.5	292
133	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. <i>Future Oncology</i> , 2014, 10, 1255-1275.	1.1	5
134	Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 931-941.	1.1	28
135	Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 710-716.	1.2	44
136	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014, 45, 1630-1638.	1.1	235
137	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 718-721.	1.4	15
138	Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. <i>Investigational New Drugs</i> , 2013, 31, 1056-1065.	1.2	6
139	Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 934-941.	1.0	17
140	A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etrinetecan Pegol in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 268-278.	3.2	48
141	Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 352-60.	0.6	8
142	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1092-1100.	3.2	78
143	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 2334-2343.	1.2	31
144	The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials. <i>Journal of Cancer</i> , 2012, 3, 345-353.	1.2	15

#	ARTICLE	IF	CITATIONS
145	Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumorsâ€”A focus on gastrointestinal malignancies.. Journal of Clinical Oncology, 2012, 30, 249-249.	0.8	3
146	2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen. Blood, 2012, 120, 4723-4723.	0.6	0
147	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2011, 17, 2502-2511.	3.2	499
148	Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. Cancer, 2011, 117, 3276-3283.	2.0	4
149	Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 3431-3442.	3.2	29
150	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2011, 17, 2997-3004.	3.2	132
151	Reply to M. Buyse et al. Journal of Clinical Oncology, 2011, 29, e453-e453.	0.8	2
152	A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m ² Administered Weekly as a 30â€”Minute Intravenous Infusion in Patients With Cancer. Journal of Clinical Pharmacology, 2010, 50, 268-275.	1.0	8
153	Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-Î² in Rodents and Nonhuman Primates. Human Gene Therapy, 2010, 21, 451-462.	1.4	62
154	Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. Journal of Clinical Oncology, 2010, 28, 4877-4883.	0.8	552
155	Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series. Case Reports in Gastroenterology, 2009, 3, 67-71.	0.3	13
156	Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. New England Journal of Medicine, 2009, 361, 1164-1172.	13.9	1,054
157	Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale Journal of Biology and Medicine, 2009, 82, 1-6.	0.2	46
158	The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 2003, 9, 1136-44.	3.2	312